A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF CBL-514 INJECTION FOR REDUCING ABDOMINAL SUBCUTANEOUS FAT

Registry ID

CBL-0301

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

CALIWAY BIOPHARMACEUTICALS CO., LTD.

Start date

2025-09-01

Last update

2025-08-08

Conditions

• ABDOMINAL SUBCUTANEOUS FAT

Related clinical trials

• A PHASE 2B, RANDOMIZED, PLACEBO-CONTROLLED FACTORIAL STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF CBL-514 INJECTION COMPARED WITH CBL-A1 AND CBL-A2 FOR REDUCING ABDOMINAL SUBCUTANEOUS FAT

View on source registry